CIK 1657134
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2021-Q3. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 35.98% | 8 |
| Unclassified | 35.48% | 11 |
| Insurance | 13.64% | 2 |
| Life Sciences Tools & Services | 9.86% | 2 |
| Health Care Providers & Services | 5.04% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | BMRN | BIOMARIN PHARMACEUTICAL INC | Health Care | 8.34% |
| 2 | HORIZON THERAPEUTICS PLC | Unclassified | 7.87% | |
| 3 | UNH | UNITEDHEALTH GROUP INC | Financials | 7.16% |
| 4 | ABBV | AbbVie Inc. | Health Care | 6.79% |
| 5 | IQV | IQVIA HOLDINGS INC. | Health Care | 6.64% |
| 6 | CNC | CENTENE CORP | Financials | 6.48% |
| 7 | BELLUS HEALTH INC NEW | Unclassified | 5.47% | |
| 8 | CYTK | CYTOKINETICS INC | Health Care | 5.44% |
| 9 | JNJ | JOHNSON & JOHNSON | Health Care | 5.06% |
| 10 | NTRA | Natera, Inc. | Health Care | 5.04% |
13/24 names classified · sector 64.5% of weight · industry 64.5% · mkt cap 60.6%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 64.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 34% of book weight classified — the grid is NOT representative of the whole book.
Classified: 34.0% of book weight (5/14 names) · unclassified 66.0%: , CNC, CYTK, NTRA, ARGX, KURA, QTRX, ACRS, PMVP. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | BMRNBIOMARIN PHARMACEUTICAL INC | 177,741 | $16M | 8.3% | NEW |
| 2 | HORIZON THERAPEUTICS PLC | 137,610 | $15M | 7.9% | ADD 452% |
| 3 | UNHUNITEDHEALTH GROUP INC | 26,844 | $13M | 7.2% | NEW |
| 4 | ABBVABBVIE INC | 94,448 | $13M | 6.8% | NEW |
| 5 | IQVIQVIA HLDGS INC | 44,314 | $13M | 6.6% | NEW |
| 6 | CNCCENTENE CORP DEL | 148,254 | $12M | 6.5% | NEW |
| 7 | BELLUS HEALTH INC NEW | 1,280,757 | $10M | 5.5% | ADD 19% |
| 8 | CYTKCYTOKINETICS INC | 225,032 | $10M | 5.4% | TRIM −9% |
| 9 | JNJJOHNSON & JOHNSON | 55,755 | $10M | 5.1% | NEW |
| 10 | NTRANATERA INC | 101,674 | $9M | 5.0% | NEW |
| 11 | AMICUS THERAPEUTICS INC | 716,709 | $8M | 4.4% | ADD 10% |
| 12 | ARGXARGENX SE | 20,881 | $7M | 3.9% | NEW |
| 13 | KURAKURA ONCOLOGY INC | 502,275 | $7M | 3.7% | ADD 158% |
| 14 | APELLIS PHARMACEUTICALS INC | 139,445 | $7M | 3.5% | NEW |
| 15 | MIRATI THERAPEUTICS INC | 43,876 | $6M | 3.4% | ADD 4% |
| 16 | IVERIC BIO INC | 375,989 | $6M | 3.3% | ADD 6% |
| 17 | QTRXQUANTERIX CORP | 143,204 | $6M | 3.2% | TRIM −12% |
| 18 | ITEOS THERAPEUTICS INC COM | 104,755 | $5M | 2.6% | ADD 83% |
| 19 | DICE THERAPEUTICS INC | 185,201 | $5M | 2.5% | TRIM −33% |
| 20 | AVADEL PHARMACEUTICALS PLC | 369,134 | $3M | 1.6% | TRIM −22% |
| 21 | ACRSACLARIS THERAPEUTICS INC | 198,493 | $3M | 1.5% | TRIM −18% |
| 22 | PMVPPMV PHARMACEUTICALS INC | 97,680 | $2M | 1.2% | TRIM −3% |
| 23 | REGULUS THERAPEUTICS INC | 2,731,044 | $860,000 | 0.5% | ADD 95% |
| 24 | BCLS ACQUISITION CORP | 71,372 | $699,000 | 0.4% | TRIM −3% |
Where this firm's principals came from and which firms its alumni went on to found.
